ClinicalTrials.gg
RecruitingNCT07409454CAREMM-007Updated Aug 7, 2026

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

A Phase 2 interventional study of anti-BCMA/CD3 bispecific antibody in Multiple Myeloma, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China — 32 open to participants now, 35 under way, none of them phase 3. Multiple Myeloma · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
20th of 36
20 · median 24
Started
2026
with 15 others
Phase 2
18 of 40
15 open now
Primary completion
2027-12
later than 23 of 34 live
Registered
26th of 40
by date

Among the 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China, this one is the 20th largest by planned enrollment of the 36 interventional ones that give a count, is one of 16 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 23 of the 34 other live ones, and was the 26th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

32 of the 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • BCMA/CD3 bispecific antibody
  • multiple myeloma
  • CM336
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand and voluntarily signs the form (ICF).
  2. Age ≥ 18 years.
  3. Newly diagnosed multiple myeloma according to the International Myeloma Working Group (IMWG) criteria.
  4. MRD positivity (≥10-⁵) detected by EuroFlow.
  5. Previous therapy limited to treatment only, including: (1) Induction therapy with a 3- or 4-drug regimen containing a proteasome inhibitor and/or an immunomodulatory drug and/or an anti-CD38 monoclonal antibody; (2) Single or tandem stem cell transplantation (ASCT); (3) Up to 2-4 cycles of consolidation therapy post-ASCT are permitted, with the total number of induction plus consolidation cycles not exceeding 8.
  6. Completion of ASCT within ≤12 months from the start of induction therapy; and ≤6 months from the most recent ASCT at enrollment (≤7 months if consolidation therapy was administered).
  7. No prior maintenance therapy.
  8. Achieved at least a partial response (≥PR) according to the IMWG 2016 response criteria.
  9. Presence of at diagnosis.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with genetically modified adoptive cellular therapy.
  2. History of stem cell transplantation or solid organ transplantation.
  3. Disease progression prior to enrollment (per IMWG 2016 response criteria), or presence of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome, or light-chain amyloidosis not attributable to symptomatic multiple myeloma.
  4. Central nervous system involvement.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    BsAbs-treatment group

    Drug: anti-BCMA/CD3 bispecific antibody

Interventions

06

What researchers measure

Primary outcomes

  1. Minimal residual disease (MRD) negativity conversion rate

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of MRD negativity

    Time frame: Up to 24 months

  2. Progression-Free Survival

    Time frame: From enrollment to the date of disease progression or death, up to approximately 24 months.

  3. Overall Survival (OS)

    Time frame: From start of treatment until death from any caus, up to approximately 24 months.

  4. Incidence and severity of adverse events (AEs)

    Time frame: From the first dose through 30 days after the last dose, up to approximately 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 17 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Feb 13, 2026
StartActual
Jul 7, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409454
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Jul 7, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 7, 2026

Study contacts

An Gang, PhD&MD
Contact
angang@ihcams.ac.cn
86-022-23909171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BCMA/CD3 Bispecific Monoclonal Antibody

Start the discussion